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New York, NY, USA ; and New Delhi, IndiaMore than 400 years ago King James I of Great
Britain identified the dangers of tobacco smoking.
He said with great foresight that ‘‘Smoking is a cus-
tom loathsome to the eye, hateful to the nose,
harmful to the brain, dangerous to the lungs, and
in the black, stinking fume thereof nearest resem-
bling the horrible stygian smoke of the pit that is
bottomless’’ [1]. This attack on tobacco use from
King James I shows that concern against the ill ef-
fects of tobacco began as soon as its use began to
spread. It is now well known that tobacco use in-
creases the risk of cardiovascular diseases (CVDs),
chronic obstructive pulmonary diseases, cancer,
and adversely impacts quality of life, resulting in a
huge socio-economic concern for modern societies.
In the 20th century, smoking was the second lead-
ing cause of death after wars [2]. Similar to vectors
such as the anopheles mosquitoes, which cause ma-
laria, tobacco companies have been observed to have
the widest outreach disregarding international
boundaries, regulations, and conventions. Accord-
ing to a 2003 WHO report [3], 6 million people
die every year globally because of tobacco use and
this death toll from tobacco will increase to 10 mil-
lion deaths per year in the next two decades if the
current trends continue. This report estimates that
1 billion deaths would occur in the 21st century
due to tobacco use, and by the year 2030 1 in every
6 individuals will die because of the ill effects of to-
bacco. Currently, 48% of men and 12% of women
worldwide smoke tobacco with developing coun-
tries being the biggest contributors.
Substantial evidence has accumulated in the last
50 years regarding the pathophysiology and mecha-
nism of disease causation by tobacco and its products
[4]. Cigarette smoke contains around 4,000 poisons,
in which nicotine, carbon monoxide, oxygen free
radicals, and raised fibrinogen are the main assault
weapons, all of which increase atherosclerosis. Re-
cent evidence suggests that smoking is also relatedto metabolic disorders such as impaired glucose tol-
erance, type 2 diabetes mellitus, and central adipos-
ity. Results from INTERHEART, a large
international case–control study of incident myocar-
dial infarction matched against normal controls, has
shown middle-aged individuals who smoke have a
10-fold greater risk of sudden cardiac death as com-
pared to non-smokers [5]. Further, it demonstrated
a linear increase in the risk of myocardial infarction
with increases in the number of cigarettes smoked
per day. In addition, the INTERHEART study also
showed that chewing and other non-smoking forms
of tobacco and non-cigarette forms as smoking such
have a similar propensity to cigarette smoking in
increasing the risk of myocardial infarction.
Although women are less likely to smoke than
men, smoking-related mortality and morbidity is
evident in them as well. According to a 2001 U.S.
Surgeon General’s Report [6], women smokers have
a high risk of early heart attack and risk increases
with the number of cigarettes smoked and duration
of smoking. The incidence rate (per 100,000) of
stroke among a cohort of 118,538 women was
49.8% for smokers as compared to 17.7% for non-
smokers [7]. Along with active smokers, smoking
has its ill effects on the passive smokers as well. A
meta-analysis of 18 studies conducted by He et al.,
showed passive smokers are at 25% excess risk of
coronary diseases. Increased arterial thickening has
been reported among passive smokers in the ARIC
(Atherosclerosis Risk in Community) study [8].
Older smoking adults continue to be at risk for pre-
mature mortality due to CVD, in whom associated
problems such as diabetes, osteoporosis, and respira-
tory diseases are also exaggerated.
Systematic review of literature suggests that old-
er adults are receptive to smoking cessation and
have high quit rates. Even pharmacological therapy
to quit smoking appears to be more effective in old-
er smoking adults. Despite the benefits of smoking
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J u l y 2 0 1 2 : 1 9 5 – 1 9 6cessation older adults receive suboptimal advice. A
review of Medicare patients showed only 44% re-
ceive documented smoking advice [9]. The benefits
of quitting smoking are evident for all ages, gen-
ders, regions, and ethnicities. The benefits start
within weeks of quitting smoking. Within 2
months of quitting smoking, the arterial pressure
and heart rate are lowered and by 6 months a de-
crease in the parameters for CVD risk, improved
arterial stiffness, and coronary endothelial function
are observed. By 5 years of smoking abstinence the
risk of cardiovascular death, myocardial infarction,
and stroke reaches the level of non-smokers. After
20 years of quitting smoking, inflammatory and
haemostatic markers return to normal levels and
there is a regression of atherosclerosis in peripheral
arteries [10].
The public health burden of tobacco use man-
dates the urgent need for tobacco control particu-
larly price increases and advertisement bans. In
1999, a report from the WHO showed that with
every increase of 10% in the price of tobacco prod-
ucts there will be a decrease of 40 million in num-
ber of smokers and 10 million deaths because of
tobacco worldwide with substantial benefits to
developing countries. Similarly, substantially less
numbers of cigarette consumption per capita has
been observed in countries with a ban on cigarette
advertisements as compared to those without the
ban. Meta-analysis of results from numerous stud-
ies shows there is a reduction in hospital admission
for acute coronary events after the enactment of
smoke-free legislation [11]. The WHO-Frame-work Convention on Tobacco Control (FCTC-
2005) is a good starting point and ratified by many
countries worldwide [12]. In addition, in 2008, the
WHO also provided the MPOWER strategies for
global tobacco control, which reflects and builds on
the WHO-FCTC (2005) [13]. The six proven po-
lices to reverse the global tobacco epidemic of
MPOWER include, monitoring tobacco use and
prevention policies, protecting people from tobacco
smoke, offering help to quit tobacco use, warning
about the dangers of tobacco, enforcing bans on to-
bacco advertising, promotion, and sponsorship, and
raising taxes on tobacco.
Despite all the global efforts, there appears to be
a disconnect in the way tobacco control efforts are
carried out with several countries not completely
implementing the WHO guidelines. At individual
levels, while physicians are keen to attempt biolog-
ical measures such as drugs for quitting smoking,
tobacco activists emphasize the behavioral inter-
ventions and policy measures.
In order to sensitize a wide array of stakeholders
involved in tobacco control and to provide com-
plete information on tobacco, starting from biolog-
ical and pathophysiological mechanisms at one end
to broad societal perspective on the other, we re-
quested Profs. K.S. Reddy, Christpoher Millet,
and Monkia Arora to be the guest editors of this
important issue. We congratulate them for bring-
ing such a comprehensive and complete issue that
will appeal to all our readers. We hope you will en-
joy reading this highly informative special edition
on tobacco.R E F E R E N C E S1. King James I. A counter-blast to
tobacco, London, 1604. Available at
http://www.archive.org/stream/essaye-
sofprentis00jamerich/essayesofpren-
tis00jamerich_djvu.txt. Accessed July
11, 2012.
2. World Health Organization. Fact
sheet No. 339, May 2012. Available at:
http://www.who.int/mediacentre/fact-
sheets/fs339/en/index.html. Accessed
July 11, 2012.
3. World Health Organization. The
world health report 2003 - shaping
the future. Available at: http://www.
who.int/whr/2003/en/. Accessed July
11, 2012.
4. Ambrose JA, Barua RS. The patho-
physiology of cigarette smoking and
cardiovascular disease: an update. J
Am Coll Cardiol 2004;43:1731–7.
5. Yusuf S, Hawken S, Ounpuu S, et al.
Effect of potentially modifiable riskfactors associated with myocardial
infarction in 52 countries (the
INTERHEART study): case-control
study. Lancet 2004;364:937–52.
6. Centers for Disease Control. US
Surgeon General’s Report (2001).
Available at: http://www.cdc.gov/
tobacco/data_statistics/sgr/2001/index.
htm. Accessed July 11, 2012.
7. Colditz GA, Bonita R, Stampfer MJ,
et al. Cigarette smoking and risk of
stroke in middle-aged women. N
Engl J Med 1988;318:937–41.
8. White AD, Folsom AR, Chambless
LE, et al. Community surveillance of
coronary heart disease in the Athero-
sclerosis Risk in Communities
(ARIC) Study: methods and initial
two years’ experience. J Clin Epidem-
iol 1996;49:223–33.
9. Doolan DM, Froelicher ES. Smoking
cessation interventions and olderadults. Prog Cardiovasc Nurs
2008;23:119–27.
10. Gratziou C. Respiratory, cardiovas-
cular and other physiological conse-
quences of smoking cessation. Curr
Med Res Opin 2009;25:535–45.
11. Pell JP, Haw S, Cobbe S, et al.
Smoke-free legislation and hospital-
izations for acute coronary syn-
drome. N Engl J Med
2008;359:482–91.
12. World Health Organization. WHO-
Framework Convention on Tobacco
Control, 2005. Available at: http://
www.who.int/fctc/en/. Accessed July
11, 2012.
13. World Health Organization. WHO
Report on the Global Tobacco Epi-
demic, 2011: The MPOWER Pack-
age. Geneva: World Health
Organization, 2011.
